Last reviewed · How we verify
NCT06167421
Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy
NA trial testing Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique in Pancreatic Tumor, Benign in 240 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 240 |
| Start date | 1 January 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique
- Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique
Conditions studied
- Pancreatic Tumor, Benign — all drugs for Pancreatic Tumor, Benign →
- Pancreatic Neuroendocrine Tumor — all drugs for Pancreatic Neuroendocrine Tumor →
- Solid Pseudopapillary Tumor of the Pancreas — all drugs for Solid Pseudopapillary Tumor of the Pancreas →
Sponsor
Fudan University
Who can join
Adults 18 to 70, any sex, with Pancreatic Tumor, Benign or Pancreatic Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to compare the surgical outcomes of laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique versus the Warshaw technique. The primary focus is on the rates of unplanned splenectomy, occurrence of severe complications, as well as intraoperative and perioperative outcomes of both techniques.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06167421
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06167421 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 12 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06167421.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing